论文部分内容阅读
目的探讨归芪汤对活动性肺结核红细胞免疫功能及临床疗效的影响。方法将１２０例活动性肺结核患者随机分为归芪汤组（６２例）及化疗组（５８例），两组初治肺结核采用Ｈ、Ｒ、Ｅ、Ｓ，复治肺结核采用Ｈ、Ｚ、Ｋ、１３２１Ｔｈ化疗方案。归芪汤组加服归芪汤，每日１剂水煎服。连续治疗２ｍｏ。治疗前后分别检测红细胞免疫指标、病灶范围、痰菌变化，并以３０例健康人的红细胞免疫指标作对照。结果两组肺结核患者红细胞免疫功能均低于正常人（Ｐ＜０．０１），两组治疗前后红细胞Ｃ３ｂ花环率（ＲＢＣ－Ｃ３ｂＲＲ）比较均有升高，红细胞ＩＣ花环率（ＲＢＣ－ＩＣＲ）改变不大；归芪汤组红细胞Ｃ３ｂ花环率升高幅度优于化疗组（Ｐ＜０．０１）。两组疗效比较，归芪汤组总有率９３．５４％，明显高于化疗组的４４．８３％（Ｐ＜０．００５）。痰菌转阴：归芪汤组４４例，化疗组１８例，两组比较Ｐ＜０．００５。结论归芪汤具有增强活动性肺结核患者红细胞免疫功能的作用，能提高肺结核病的治疗效果。
Objective To investigate the effect of Guiqi Decoction on red blood cell immune function and clinical efficacy of active tuberculosis. Methods One hundred and twenty patients with active pulmonary tuberculosis were randomly divided into Guizhi Decoction group (62 cases) and chemotherapy group (58 cases). The initial treatment of pulmonary tuberculosis was H, R, E, and S. Retreatment of pulmonary tuberculosis was performed using H, Z, and K. , 1321Th chemotherapy program. Return to the soup group plus service Guiqi Decoction, a daily Shuijianbi. Continuous treatment 2mo. Before and after treatment, red blood cell immune parameters, lesion range, and sputum changes were detected, and 30 healthy controls were used as controls. Results The immune function of red blood cells in two groups of pulmonary tuberculosis patients was lower than normal (P<0.01). The ratio of red blood cell C3b rosette (RBC-C3bRR) was increased before and after treatment in both groups, and the red blood cell IC rosette rate (RBC-ICR) was changed. Little; the Guiqi Tang group red blood cell rose rate of C3b rose better than the chemotherapy group (P <0.01). Comparing the efficacy of the two groups, the total rate of Guizhi Tang group was 93.54%, which was significantly higher than that of the chemotherapy group (44.83%) (P<0.005). Bacteria were negative: 44 patients in the Guiqi Decoction group and 18 patients in the chemotherapy group. The difference between the two groups was P<0.005. Conclusion Guiqi Decoction can increase the immune function of red blood cells in patients with active pulmonary tuberculosis, and can improve the therapeutic effect of pulmonary tuberculosis.